Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Gild Sciences (GILD) PT Drops to $75 at BMO on Bad Guidance
February 9, 2017 6:41 AM ESTBMO Capital Markets analyst M. Ian Somaiya maintains Market Perform rating, but drops price target on Gild Sciences (NASDAQ: GILD) to $75 (from $88), as the company delivered guidance well below consensus, forcing the Street to cut estimates.
Somaiya comments, "We are maintaining our Market... More
Gilead Sciences (GILD): 'Acquisition Wanted! - Please Apply Within'
February 8, 2017 11:09 AM ESTFollowing its 'kitchen sink' HCV guidance and subsequent 9% sell-off, the urgency for Gilead Sciences (NASDAQ: GILD) to make an acquisition continues to intensify. On the call, the company essentially admitted that it cannot grow over the next few years without a... More
Gilead Sciences (GILD) Pressured on Market Open, Shares Down 10%
February 8, 2017 9:40 AM ESTGilead Sciences (NASDAQ: GILD) Pressured on Market Open, Shares Down 10%
... MoreNeedham & Company Remains Sidelined on Gilead Sciences (GILD) Following 4Q
February 8, 2017 6:57 AM ESTNeedham & Company reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) following the company's 4Q earnings report.
Analyst Alan Carr commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by... More
Gilead Sciences (GILD) Tops Q4 EPS by 9c, Offers FY17 Guidance
February 7, 2017 4:03 PM ESTGilead Sciences (NASDAQ: GILD) reported Q4 EPS of $2.70, $0.09 better than the analyst estimate of $2.61. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.15 billion.
Full... More
